Toxicology:
With
Exemestane single dose toxicity: mice single oral dosages up to 3200mg/kg (according to body surface area, approximately 640 times the recommended clinical dose) when the death occurred. Single dose in rats and dogs, respectively 5000mg/kg and 3000mg/kg (according to body surface area, were approximately 2000 times the recommended clinical dose and 4,000 times), the animals appear dead. Mice and dogs single dose 400mg/kg respectively and 3000mg/kg (according to body surface area, were approximately 80 times the recommended clinical dose and 4,000 times), the animals convulsions.
Clinical studies, a single healthy person this product dosages up to 800mg/kg and advanced breast cancer at doses up to 600mg administered continuously at 12 weeks, have shown good tolerability.
Reproductive toxicity: 14 days before mating to gestation 15-20 days, rats were given the product, administered 21 days of lactation continues, the dose of 4mg/kg / day (according to body surface area, equivalent to the human clinical recommended dose is 1.5 fold) occurs when the placenta weight increase; doses greater than or equal to 20mg/kg / day occurs when pregnancy prolongation, abnormal or difficult childbirth, and also observed increased fetal absorption, reducing the number of live births, fetal weight reduction, delayed ossification . Gestation period of organogenesis in rats administered doses less than or equal to 810mg/kg (according to body surface area, approximately 320 times the recommended clinical dose) when no obvious teratogenic effects. Rabbits organogenesis dose 90mg/kg / day (according to body surface area, which is about the recommended human clinical dose used 70 times) occurs when the placenta weight reduction; dose of 270mg/kg / day, a miscarriage, the absorption fetal growth and fetal rabbit weight loss; doses less than or equal to 270mg/kg / day (according to body surface area, approximately 210 times the recommended clinical dose), the rabbit malformation rate has not increased. There is no effect of this product on pregnant women in clinical research data, if the pregnancy using this service, you should tell the patient the product potentially harmful to the fetus and potential risk of miscarriage.
63 days prior to mating and during caged together, male rats administered 500mg/kg / day (according to body surface area, approximately 200 times the clinically recommended amount), the administration can not mate with the female fertility in rats is reduced. This product is a dose of 20mg/kg / day (according to body surface area, the equivalent of one 8 times the recommended clinical dose) when female rats fertility parameters (such as ovarian function, mating behavior, conception rate) had no effect, but makes The average litter size decreased. In addition, the general toxicity studies, according to body surface area, human clinical dose of 3-20 times the recommended dose, mice, rats and dogs have varying degrees of ovarian changes, including hyperplasia, increased the number of ovarian cysts and reduce the number of corpus luteum.
Rats were orally administered radiolabeled 14C-exemestane 1mg/kg, found it through the placenta, 15 minutes after administration appears in breast milk with radioactivity exemestane, the dose, a single to 24 hours after treatment, the product and its metabolites in the maternal and fetal blood concentration considerably. Jhihben whether the product is not through human milk secretion. Because many drugs can be secreted in milk, therefore breast-feeding women should be careful.
Genetic Toxicity: Ames test and in V79 Chinese hamster lung cell test showed no mutagenic effect. In vitro without metabolic activation in the case of human lymphocytes exhibit mutagenic effects, but mouse micronucleus test were negative. This product does not increase the rat hepatocyte unscheduled DNA synthesis procedures.
Carcinogenicity: No carcinogenic effects of this product research data.
More about:
Exemestane sales
From:
Hormonehome